Covid-19 roundup: Top analyst pokes hole in AstraZeneca/Oxford data while scientists tamper hope for fast rollout
AstraZeneca and Oxford may have outshone Pfizer and BioNTech — at least in terms of media attention — with Phase I results on its Covid-19 vaccine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
